Immix Biopharma Sees Stock Surge on Positive Clinical Trial Results and $100M Offering

Immix Biopharma shares are trading higher after the company announced positive Phase 2 results for NXC-201, showing a 75% complete response rate, and priced an upsized $100 million underwritten offering.